November is National Alzheimer's Disease Awareness Month, a time dedicated to increasing understanding and support for individuals and families affected by this devastating disease. We believe that knowledge is power, and together, we can make a difference in the fight against Alzheimer's.
At Altium Cares, we are committed to spreading awareness about Alzheimer's disease and its impact on millions of lives.
The U.S. Food and Drug Administration (FDA) approved lecanemab (Leqembi) for people with mild Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease. A phase 3 clinical trial found that the medicine slowed cognitive decline in people with early Alzheimer's disease. Learn More Researchers say we appear to be at the start of a new era for Alzheimer’s treatment. Trial results published in January showed that, for the first time, a drug has been able to slow the cognitive decline characteristic of the disease. Learn More We believe that everyone deserves access to groundbreaking medical treatments and technologies that can significantly improve their health. With Altium Cares, we're taking tangible steps to make this vision a reality. Learn More
We believe in investing in companies that will make a meaningful difference in the world, and our commitment to this goal is reflected in everything we do. In further pursuit of our mission, we have decided to match all donations for the rest of the 2023 year. This means we are matching every dollar donated 1:1, enabling you to double your impact.
We invite you to join us in this journey of creating a better world for all.